首页> 美国卫生研究院文献>PLoS Computational Biology >Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer
【2h】

Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer

机译:药物组合敏感性评分有助于发现癌症中协同有效的药物组合

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

High-throughput drug screening has facilitated the discovery of drug combinations in cancer. Many existing studies adopted a full matrix design, aiming for the characterization of drug pair effects for cancer cells. However, the full matrix design may be suboptimal as it requires a drug pair to be combined at multiple concentrations in a full factorial manner. Furthermore, many of the computational tools assess only the synergy but not the sensitivity of drug combinations, which might lead to false positive discoveries. We proposed a novel cross design to enable a more cost-effective and simultaneous testing of drug combination sensitivity and synergy. We developed a drug combination sensitivity score (CSS) to determine the sensitivity of a drug pair, and showed that the CSS is highly reproducible between the replicates and thus supported its usage as a robust metric. We further showed that CSS can be predicted using machine learning approaches which determined the top pharmaco-features to cluster cancer cell lines based on their drug combination sensitivity profiles. To assess the degree of drug interactions using the cross design, we developed an S synergy score based on the difference between the drug combination and the single drug dose-response curves. We showed that the S score is able to detect true synergistic and antagonistic drug combinations at an accuracy level comparable to that using the full matrix design. Taken together, we showed that the cross design coupled with the CSS sensitivity and S synergy scoring methods may provide a robust and accurate characterization of both drug combination sensitivity and synergy levels, with minimal experimental materials required. Our experimental-computational approach could be utilized as an efficient pipeline for improving the discovery rate in high-throughput drug combination screening, particularly for primary patient samples which are difficult to obtain.
机译:高通量药物筛选促进了癌症中药物组合的发现。现有的许多研究都采用了完整的矩阵设计,旨在表征药物对癌细胞的作用。然而,全基质设计可能不是最佳的,因为它需要将药物对以全因子方式以多种浓度组合。此外,许多计算工具仅评估药物组合的协同作用,而不评估药物组合的敏感性,这可能会导致假阳性结果。我们提出了一种新颖的交叉设计,以实现更具成本效益的同时检测药物组合的敏感性和协同作用。我们开发了一种药物组合敏感性评分(CSS)来确定药物对的敏感性,并显示CSS在重复试验之间具有很高的可重复性,因此支持将其用作可靠的指标。我们进一步表明,可以使用机器学习方法预测CSS,该方法根据癌细胞的药物敏感性组合确定了癌细胞系的主要药理特征。为了使用交叉设计评估药物相互作用的程度,我们根据药物组合和单一药物剂量反应曲线之间的差异开发了S协同作用评分。我们表明,S评分能够以与使用完整矩阵设计相当的准确度检测真正的协同和拮抗药物组合。综上所述,我们表明,将交叉设计与CSS敏感性和S协同作用评分方法相结合,可以以最少的实验材料对药物组合敏感性和协同作用水平进行稳健而准确的表征。我们的实验计算方法可以用作提高高通量药物组合筛选中发现率的有效途径,尤其是对于难以获得的原发患者样品而言。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号